Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) CFO Paul Herendeen acquired 15,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The stock was acquired at an average price of $16.10 per share, with a total value of $241,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NYSE VRX traded down $0.35 during mid-day trading on Friday, hitting $15.44. The company had a trading volume of 5,885,825 shares, compared to its average volume of 11,976,524. The stock has a market cap of $5,508.19, a P/E ratio of 4.03, a PEG ratio of 0.33 and a beta of -0.32. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25. Valeant Pharmaceuticals International Inc has a 1-year low of $8.31 and a 1-year high of $24.43.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%. The business had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.18 billion. During the same period last year, the firm earned $1.26 earnings per share. The company’s revenue for the quarter was down 10.0% compared to the same quarter last year. equities analysts forecast that Valeant Pharmaceuticals International Inc will post 3.12 EPS for the current fiscal year.
Several research analysts recently weighed in on VRX shares. ValuEngine upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. JPMorgan Chase cut Valeant Pharmaceuticals International from a “neutral” rating to an “underweight” rating and set a $12.00 price target on the stock. in a research note on Thursday, December 14th. Mizuho upped their price target on Valeant Pharmaceuticals International from $7.00 to $10.00 and gave the stock an “underperform” rating in a research note on Friday, December 15th. Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Tuesday, December 26th. Finally, Wells Fargo restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Thursday, January 4th. Five analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $18.56.
A number of institutional investors have recently bought and sold shares of VRX. Northern Trust Corp raised its stake in Valeant Pharmaceuticals International by 63.7% in the second quarter. Northern Trust Corp now owns 326,013 shares of the specialty pharmaceutical company’s stock valued at $5,640,000 after buying an additional 126,851 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Valeant Pharmaceuticals International by 25.0% during the third quarter. Nationwide Fund Advisors now owns 65,480 shares of the specialty pharmaceutical company’s stock worth $938,000 after purchasing an additional 13,080 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Valeant Pharmaceuticals International during the third quarter worth about $490,000. Andra AP fonden grew its holdings in shares of Valeant Pharmaceuticals International by 35.0% during the third quarter. Andra AP fonden now owns 98,800 shares of the specialty pharmaceutical company’s stock worth $1,767,000 after purchasing an additional 25,600 shares during the last quarter. Finally, Gabelli Funds LLC grew its holdings in shares of Valeant Pharmaceuticals International by 49.3% during the third quarter. Gabelli Funds LLC now owns 91,088 shares of the specialty pharmaceutical company’s stock worth $1,305,000 after purchasing an additional 30,088 shares during the last quarter. Institutional investors own 50.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/valeant-pharmaceuticals-intl-inc-vrx-cfo-purchases-241500-00-in-stock.html.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.